Karen Wheeler
Urology · Tucson, AZNPI 1669738811
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,962 of the $7,505 with a category attached, or 66.1%. It is spread thinly across 47 manufacturers, the largest accounting for just 20.8%. Reporting peaked in 2024 at $3,997 and has fallen 74.3% since, to $1,027 in 2025.
Across 194 payments — averaging $38.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$2K
- Ferring Pharmaceuticals AS$1K
- Boston Scientific$532
- Bayer$486
- Dendreon Pharmaceuticals LLC$430
- Sumitomo Pharma America, Inc.$406
- plus $3K from 41 others
Across 2 payments — averaging $7250.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$15K
What the payments were for
- Consulting fees$1,55821%
- Travel & lodging$98413%
- Food & beverage$4,96266%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ADSTILADRIN$1,411
- JELMYTO$125
- PROVENGE$122
- AquaBeam Robotic System$121
- GENERAL - THERAPIES$115
- LithoVue Elite$110
- LithoVue$100
How this compares
$7,505 in reported general payments places this provider in the 70th percentile of 269 urology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrgovyxRelugolix | 16 | $42,085 |
| MyrbetriqMirabegron | 36 | $24,699 |
| GemtesaVibegron | 25 | $15,827 |
| Abiraterone Acetate | 11 | $10,205 |
| Finasteride | 180 | $2,277 |
| Methenamine Hippurate | 17 | $1,665 |
| Tamsulosin Hcl | 142 | $1,632 |
| Estradiol | 17 | $1,065 |
| NitrofurantoinNitrofurantoin Macrocrystal | 18 | $611 |
| Testosterone Cypionate | 17 | $516 |
| Ciprofloxacin Hcl | 90 | $368 |
| Cephalexin | 43 | $327 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 16 | $281 |
| Tadalafil | 12 | $201 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 20 | $157 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $406 | $57,91241 claims |
| Astellas Pharma US IncMyrbetriq | $46 | $24,69936 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $68 | $10,20511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 269 urology providers in Arizona.
Other urology in Tucson
- Mitzi BarmatzTucson$135K
- Curtis DunsheeTucson$46K
- Susan KalotaTucson$30K
- Kalpesh PatelTucson$26K
- Tristan BerryTucson$14K
- Aleksandar BlubaumTucson$11K
- Mitchell HumphreysPhoenix$358K
- Shawn BlickGoodyear$336K
- Daniel JaffeePhoenix$280K
- Rahul MehanMesa$277K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.